Oncothyreon (ONTY) Reports Worse-Than-Expected Q3 Loss of $0.24
More News related to ONTY
- Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
- After-Hours Movers 11/11: COMS, JMBA, GRRF, CTRP, UBET Higher; GMCR, PDC, BZ, ONTY, BRCD, TTEK Lower
- Oncothyreon (ONTY) Reports Worse-Than-Expected Q3 Loss of $0.24
- Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
- Trading Radar for 11/11: Macy's (M), Progressive (PGR), Advanced Auto Parts (AAP), Computer Sciences (CSC) Report
Oncothyreon Inc. (NASDAQ: ONTY) reports Q3 loss of $0.24, versus the analyst estimate of ($0.15). Revenue for the quarter was $4,000, which compares to the estimate of $20,000.
Related Categories
EarningsStocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
